Bayer Chagas 16 Nov.jpg” />

Bayer has announced a Phase III CHICO study of Nifurtimox to treat children of all age groups with Chagas disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Nifurtimox is a newly developed medicine by Bayer and is enlisted as one of the 'Essential Medicines' by the World Health Organisation for both adults and children.

Chagas is an infectious disease caused by single-cell parasites (trypanosoma), which spreads through the faeces / urine of kissing bugs or triatomines.

It can also be transmitted by infected blood transfusions, organ transplantation, or during pregnancy / birth from the infected mother to her unborn child.

See Also:

The Chagas disease in children treated with nifurtimox (CHICO) study will be conducted as a prospective, historically controlled study to test the efficacy, safety and pharmacokinetics of Nifurtimox for the treatment of children with Chagas disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"As the manufacturer of Nifurtimox, we have a long-term commitment to the fight against this disease."

The study will enrol 390 pediatric patients, including newborn babies.

Bayer pharmaceuticals division president and member of the board of management Dieter Weinand said: "As the manufacturer of Nifurtimox, we have a long-term commitment to the fight against this disease.

"Children are the most vulnerable patient group. Every child who can be treated is a step toward getting the disease under control."

The two-arm study will have a 30-day and 60-day treatment cycles against historical untreated control and intends to determine an appropriate, weight-adjusted dose of Nifurtimox for newborns and children using fast-disintegrating 30mg and 120mg tablets, which will be divided among weight-adjusted dosing in all age groups.

Image: Photomicrograph of Trypanosoma cruzi. Photo: courtesy of Dr. Myron G. Schultz.